Dihydro-5-azacytidine and cisplatin in the treatment of malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B.

@article{Samuels1998Dihydro5azacytidineAC,
  title={Dihydro-5-azacytidine and cisplatin in the treatment of malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B.},
  author={Brian L Samuels and James E. Herndon and David C. Harmon and Robert T. Carey and Joseph Aisner and Joseph M. Corson and Yoshihiko Suzuki and Mark L. Green and Nicholas John Vogelzang},
  journal={Cancer},
  year={1998},
  volume={82 8},
  pages={
          1578-84
        }
}

• Brian L Samuels, James E. Herndon, +6 authors Nicholas John Vogelzang
• Published 1998 in Cancer

BACKGROUND In a prior Cancer and Leukemia Group B (CALGB) Phase II trial of patients with advanced, previously untreated mesothelioma, dihydro-5-azacytidine (DHAC) demonstrated a 17% response rate, including 1 complete response, with only mild myelosuppression. This Phase II study (CALGB 9031) was conducted to determine the effectiveness of and toxicities that would result from adding cisplatin to DHAC administered to the same patient population. METHODS Thirty-six patients were treated with… CONTINUE READING

Save to Library

Create Alert

Cite

View on PubMed